Abstract
γ-Secretase modulation holds the promise for the development of a disease-modifying therapy for Alzheimers disease (AD). This novel concept of manipulating the cleavage specificity of the γ-secretase enzyme by pharmacological means implies that steady state levels of the potentially disease-causing amyloid-β(1-42) peptide can be lowered without the undesired side effects associated with full inhibition of this aspartyl-type protease. Following on from the initial discovery that certain non-steroidal anti-inflammatory drugs (NSAIDs) exhibit properties characteristic of γ-secretase modulators, this class of compounds has been extensively studied and exploited, leading to the discovery of NSAIDs derivatives endowed with improved potency for the reduction of amyloid-β(1-42) peptide production. In addition, a very limited number of non-NSAID derived γ-secretase modulators has also been recently claimed in the patent literature, suggesting that only a restricted number of pharmacophores might be involved in the modulation of γ-secretase.
Current Topics in Medicinal Chemistry
Title: γ-Secretase Modulation and its Promise for Alzheimers Disease: a Medicinal Chemistry Perspective
Volume: 8 Issue: 1
Author(s): Ilaria Peretto and Elena La Porta
Affiliation:
Abstract: γ-Secretase modulation holds the promise for the development of a disease-modifying therapy for Alzheimers disease (AD). This novel concept of manipulating the cleavage specificity of the γ-secretase enzyme by pharmacological means implies that steady state levels of the potentially disease-causing amyloid-β(1-42) peptide can be lowered without the undesired side effects associated with full inhibition of this aspartyl-type protease. Following on from the initial discovery that certain non-steroidal anti-inflammatory drugs (NSAIDs) exhibit properties characteristic of γ-secretase modulators, this class of compounds has been extensively studied and exploited, leading to the discovery of NSAIDs derivatives endowed with improved potency for the reduction of amyloid-β(1-42) peptide production. In addition, a very limited number of non-NSAID derived γ-secretase modulators has also been recently claimed in the patent literature, suggesting that only a restricted number of pharmacophores might be involved in the modulation of γ-secretase.
Export Options
About this article
Cite this article as:
Peretto Ilaria and Porta La Elena, γ-Secretase Modulation and its Promise for Alzheimers Disease: a Medicinal Chemistry Perspective, Current Topics in Medicinal Chemistry 2008; 8 (1) . https://dx.doi.org/10.2174/156802608783334097
DOI https://dx.doi.org/10.2174/156802608783334097 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology Clinical Applications of Myostatin Inhibitors for Neuromuscular Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?
Current Drug Targets Dietary Antioxidants Significantly Reduced Phorbol Myristate Acetate Induced Oxidative Stress of Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis
Current Rheumatology Reviews Azo Reductase- Activated Colon- Targeting Prodrugs of Aminosalicylates for Inflammatory Bowel Disease: Preparation, Pharmacokinetic and Pharmacodynamic Profile
Inflammation & Allergy - Drug Targets (Discontinued) The Design of Cationic Lipids for Gene Delivery
Current Pharmaceutical Design Antioxidant and ‘Natural Protective’ Properties of Kiwifruit
Current Topics in Medicinal Chemistry Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy
Current Drug Targets Inhibitors of Tyrosine Kinases in the Treatment of Psoriasis
Current Pharmaceutical Design Involvement of Cysteine Protease Inhibitors in the Defense Mechanism Against Parasites
Medicinal Chemistry PPAR-γ Agonists in Polycystic Kidney Disease with Frequent Development of Cardiovascular Disorders
Current Molecular Pharmacology Does Inhaled Corticosteroid Treatment Result in a Secondary Immune Deficiency Predisposing To Recurrent Infections?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Topical Imiquimod: Mechanism of Action and Clinical Applications
Mini-Reviews in Medicinal Chemistry Various Carbonic Anhydrases in Physiopathological Events, Carbonic Anhydrase Inhibitors, and Hybrid Compounds
Letters in Drug Design & Discovery Oxidative and Nitrosative Stress and Immune-inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)
Current Neuropharmacology IDO+ DCs and Signalling Pathways
Current Cancer Drug Targets Hydroxamic Acids, Recent Breakthroughs in Stereoselective Synthesis and Biological Evaluations
Current Organic Synthesis Ocular Vascular Involvement in the Rheumatic Diseases
Current Rheumatology Reviews Editorial [Hot Topic: Current Drug Targets for the Critically Ill COPD Patient (Guest Editors: Demosthenes Makris and Epaminondas Zakynthinos)]
Current Drug Targets Bacopa monnieri Supplements Offset Paraquat-Induced Behavioral Phenotype and Brain Oxidative Pathways in Mice
Central Nervous System Agents in Medicinal Chemistry